<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03115489</url>
  </required_header>
  <id_info>
    <org_study_id>F151214004</org_study_id>
    <nct_id>NCT03115489</nct_id>
  </id_info>
  <brief_title>Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus</brief_title>
  <official_title>Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus- a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will investigate the efficacy of the NMDA receptor antagonist ketamine as a first
      line agent in refractory status epilepticus versus traditional general anesthetic agents used
      for burst suppression that target the GABA adrenergic receptors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The traditional treatment for refractory status epilepticus includes diazepam, midazolam,
      valproic acid, thiopental and propofol. These medications fail to control seizure activity in
      20-40% of patients. This is attributed to decrease in activity of GABA receptors along with
      reciprocal up regulation of NMDA receptors. Glutamate activation of NMDA receptors promotes
      calcium influx and excitotoxicity. Ketamine, an intravenous anesthetic agent which is a
      non-competitive antagonist of NMDA receptors can block the flow of Ca and Na and by combining
      with phencyclidine binding sites inside the ion channel of NMDA receptors, reduce the
      epileptiform burst discharges and after potential. Therefore, targeting the NMDA receptors
      with ketamine may provide a novel approach to control refractory seizures. Moreover, by
      blocking glutamate mediated NMDA receptor induced neurotoxicity, ketamine may render
      neuroprotection. Ketamine also provides additional advantage of hemodynamic stability.
      Currently, ketamine is used as a last resort drug in the treatment of refractory status
      epilepticus.

      The specific aim is to determine whether continuous infusion of ketamine as a first line
      agent for refractory status epilepticus is effective in controlling seizures.

      The central hypothesis of our proposal is that early treatment with ketamine will be much
      more efficacious in controlling refractory status compared to the traditional treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2017</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time taken for burst suppression</measure>
    <time_frame>Baseline to 1 hr</time_frame>
    <description>Average time for burst suppression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time taken for termination of seizures</measure>
    <time_frame>Baseline to 24 hrs</time_frame>
    <description>Average time for seizures to terminate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Use of vasopressors</measure>
    <time_frame>baseline to 72 hrs</time_frame>
    <description>The need of vasopressors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days on ventilator</measure>
    <time_frame>Baseline to 72 hrs</time_frame>
    <description>Total number of days patient is on the ventilator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in ICU</measure>
    <time_frame>Baseline to 72 hrs postoperatively</time_frame>
    <description>Total number of days in the ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of parenteral or enteral nutrition</measure>
    <time_frame>Baseline to 72 hrs postoperatively</time_frame>
    <description>Nutrition provided through a feeding tube or catheter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical imaging results</measure>
    <time_frame>Post-op Day 2 to Post-op day 10</time_frame>
    <description>MRI scans 7 to 10 days after burst suppression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>baseline to post-op day 10</time_frame>
    <description>death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Refractory Epilepsy</condition>
  <arm_group>
    <arm_group_label>Traditional Treatment (Group T)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group T patients will be placed into burst suppression with the traditional drug infusions which include any single or combination of drugs; usually benzodiazepines, barbiturates and or propofol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine Infusion (Group K)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the group K arm will receive a loading dose of 2.5 mg/kg of ketamine followed by a continuous infusion with a starting dose of 3mg/kg/hr with titration in 1mg/kg/hr increments until burst suppression is achieved or a maximum dose of 10mg/kg/hr is reached. After 48 hours of burst suppression the ketamine dosage will be reduced by 2mg/kg/hr in a stepwise fashion to evaluated for EEG or clinical evidence of seizure recurrence.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Traditional Treatment (Group T)</intervention_name>
    <description>Patients will receive traditional drug infusions</description>
    <arm_group_label>Traditional Treatment (Group T)</arm_group_label>
    <other_name>benzodiazepines, barbiturates, propofol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine Infusion (Group K)</intervention_name>
    <description>Patients will receive loading dose of 2.5 mg/kg of ketamine followed by a continuous infusion with a starting dose of 3mg/kg/hr with titration in 1mg/kg/hr increments until burst suppression is achieved or a maximum dose of 10mg/kg/hr is reached</description>
    <arm_group_label>Ketamine Infusion (Group K)</arm_group_label>
    <other_name>Ketalar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients more than 18 years of age with a diagnosis of status epilepticus

          -  Considered for burst suppression therapy after failing 2 or 3 anti-epileptic
             medications

        Exclusion Criteria:

          -  Post anoxic status epilepticus

          -  Pregnant women, as confirmed by urine, or blood HCG, ultrasound or physical exam

          -  Prisoners

          -  Age less than 18 years

          -  Allergy or sensitivity to the drug in question
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vinodkumar Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alicia L Kindred, MS</last_name>
    <phone>205-934-4711</phone>
    <email>aliciakindred@uabmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ayesha Bryant, MD</last_name>
    <phone>205-996-7383</phone>
    <email>asbryant@uabmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UAB Department of Anesthesiology and Perioperative Medicine</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Kindred, MS</last_name>
      <phone>205-934-4711</phone>
      <email>aliciakindred@uabmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ayesha Bryant, MSPH, MD</last_name>
      <phone>205-996-7383</phone>
      <email>asbryant@uabmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Vinodkumar Singh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angela Douglas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Casey May, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>May 22, 2017</last_update_submitted>
  <last_update_submitted_qc>May 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Vinodkumar Singh</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>seizure</keyword>
  <keyword>glutamate activation</keyword>
  <keyword>N-Methyl D-Aspartate</keyword>
  <keyword>GABA receptor</keyword>
  <keyword>Ketamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Status Epilepticus</mesh_term>
    <mesh_term>Drug Resistant Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Anticonvulsants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

